Introduction
============

Cervical cancer is the most common gynaecological tumor, with estimated 527,600 new cases and 265,700 deaths in 2012 worldwide [@B1]. Most early cervical cancers could be cured by surgery [@B2]. However, for those cervical cancer patients in later stages, there are no effective therapeutic strategies and the survival rate of these cervical cancer patients is only about 15% [@B3]. Therefore, novel early diagnostic and therapeutic approaches are urgently needed.

Serum non-invasive diagnostic biomarkers have been commonly used for early diagnosis of various cancers, such as α-fetoprotein (AFP) for liver cancer, prostate-specific antigen (PSA) for prostate cancer [@B4], [@B5]. Although several serum biomarkers are also used for diagnosis of cervical cancer, such as carbohydrate antigen 125 (CA125) and squamous cell carcinoma antigen (SCC Ag), the diagnostic sensitivity and specificity are not satisfactory and limit their utility [@B6], [@B7]. Thus, identifying novel sensitive and specific serum biomarkers are critical for the early diagnosis of cervical cancer.

Except for these well-known proteins AFP, PSA, CA125 and so on, many long noncoding RNAs (lncRNAs) are also detected in the serum and could be used as diagnostic biomarkers for cancers [@B8]-[@B12]. LncRNA is a class of RNA molecules with no protein coding potential and longer than 200 nucleotides in length [@B13]-[@B15]. Next-generation sequencings of human genome and transcriptome have demonstrated that the number of lncRNAs is much larger than that of mRNAs, with about 58,000 different lncRNAs and 21,000 different mRNAs [@B16], [@B17]. Accumulating evidences displayed that many lncRNAs are involved in various pathophysiological processes, including cancers [@B18]-[@B21]. Many lncRNAs are frequently dysregulated in various cancer tissues [@B22]-[@B26]. Furthermore, several lncRNAs have been found in the serum and could be used as diagnostic biomarkers for cancers, such as PVT1 for cervical cancer [@B9]; UCA1 and WRAP53 for liver cancer [@B10]; H19 and PTPEN1 for gastric cancer [@B8], [@B11]; XIST and HIF1A-AS1 for non-small cell lung cancer [@B12]. In addition, a variety of lncRNAs function as oncogenes or tumor-suppressors in cancers [@B27]-[@B29]. They promote or inhibit cell proliferation, cell apoptosis, cell cycle, cell migration, cell invasion, drug resistance and so on [@B30]-[@B32]. Targeting these lncRNAs represent novel therapeutic strategies for cancers.

LncRNA GIHCG is first identified in liver cancer, which is up-regulated in liver cancer and promotes liver cancer cell proliferation and migration, and liver cancer growth and metastasis *in vivo* [@B33]. Our previous study found that GIHCG is also up-regulated in renal cell carcinoma (RCC) tissues and depletion of GIHCG represses RCC cell proliferation and migration [@B34]. Furthermore, we identified the existence of GIHCG in human serum and found that GIHCG is up-regulated in the serum of RCC patients and could serve as a diagnostic biomarker for RCC [@B34]. However, the expression, roles, and clinical significances of GIHCG in cervical cancer are still unknown.

In this study, we investigated the expression of GIHCG in cervical cancer tissues and cell line, and also in the serum of cervical cancer patients and healthy controls. Using gain-of-function and loss-of-function assays, we investigated the roles of GIHCG in cervical cancer cell proliferation, apoptosis, and migration *in vitro* and tumor growth *in vivo*. Moreover, the underlying mechanisms mediating the roles of GIHCG in cervical cancer are also explored.

Materials and methods
=====================

Clinical samples
----------------

Fifty-eight pairs of cervical cancer tissues and adjacent normal tissues were obtained from cervical cancer patients who received surgery at Fuzhou General Hospital, Fuzhou, Fujian, China from December 2014 to December 2017. All the tissues were frozen in liquid nitrogen immediately after surgery and stored at -80°C until use. All samples were confirmed by pathological examination. Venus blood was collected in serum separator tubes from 80 cervical cancer patients before surgery and 80 age-matched healthy controls at The People\'s Hospital of Yichun City, Yichun, Jiangxi, China from December 2014 to December 2017. Then, the tubes were centrifugated at 3000 rpm for 15 min at 4°C to collect serum. The serum samples were divided into multiple aliquots of 500 µl each and stored at -80°C until use. All the clinical samples were acquired with informed consent from the participants. The Ethics Review Committee of Fujian Medical University reviewed and approved the use of clinical samples.

Cell culture
------------

The human normal cervical epithelial cell line HCerEpiC was acquired from ScienCell Research Laboratories (Carlsbad, CA, USA) and cultured in Cervical Epithelial Cell Growth Supplement (ScienCell). The cervical cancer cell lines HeLa, SiHa, C-33A, and CaSki were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). HeLa, SiHa, and C-33A cells were cultured in Eagle\'s Minimum Essential Medium (Gibco, Carlsbad, CA, USA). CaSki cells were cultured in RPMI-1640 Medium (Gibco). All the cells were grown in the above described medium supplemented with 10% fetal bovine serum (Gibco) at an incubator with a humidified atmosphere of 5% CO~2~ at 37°C.

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)
-----------------------------------------------------------------------------

Total RNA was extracted from indicated tissues and cells with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer\'s protocol. First-strand cDNA was generated using the extracted RNA and the M-MLV Reverse Transcriptase (Invitrogen) in accordance with the manufacturer\'s protocol. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the SYBR Premix Ex Taq™ II (Takara, Dalian, Liaoning, China) on StepOnePlus™ Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA) with the standard SYBR-Green PCR protocols. β-actin was employed as an endogenous control for quantification of GIHCG. The primer sequences are as follows: for GIHCG, 5\'-CTTTCAAGAAGTTTGGCTGTC-3\' (sense) and 5\'-GCTCATTCAACGGATAAGTC-3\' (anti-sense); for β-actin, 5\'-TCCTCTCCCAAGTCCACACA-3\' (sense) and 5\'-GCACGAAGGCTCATCATTCA-3\' (anti-sense). For the quantification of miR-200b, qRT-PCR was performed using TaqMan microRNA assays (Applied Biosystems) in accordance with the manufacturer\'s protocol. U6 was employed as an endogenous control for quantification of miR-200b. The expression of GIHCG and miR-200b was calculated with the comparative cycle threshold (CT; 2^-ΔΔCT^) method.

Vectors construction, small interfering RNA (siRNA) synthesis and transfection
------------------------------------------------------------------------------

GIHCG overexpression vector pcDNA3.1-GIHCG was constructed as previously described [@B33]. Briefly, the cDNA encoding GIHCG was PCR-amplified with the Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher, Waltham, MA, USA) and subcloned into the Hind III and BamH I sites of pcDNA3.1 empty vector (Invitrogen). The primers sequences are as follows: 5\'-CCCAAGCTTGGAGGAGTTACGCAGGCAGGGTT-3\' (sense) and 5\'-CGGGATCCGATTTAATGATGTATACTTCTATATTAG-3\' (anti-sense).

The siRNAs specifically targeting GIHCG and control siRNA were acquired from GenePharma (Shanghai, China) and have been used in our previous report [@B34]. The transfection of vectors and siRNAs was performed with Lipofectamine 3000 (Invitrogen) in accordance with the manufacturer\'s protocol.

Stable cell lines construction
------------------------------

To construct GIHCG stably overexpressed HeLa cells, pcDNA3.1-GIHCG or pcDNA3.1 was transfected into HeLa cells. Seventy-two hours after transfection, the cells were selected with neomycin for four weeks. To construct miR-200b and GIHCG concurrently stably overexpressed HeLa cells, GIHCG stably overexpressed HeLa cells were infected with miR-200b overexpression lentivirus (GeneChem, Shanghai, China) and selected with puromycin for four weeks.

Cell proliferation assays
-------------------------

Cell proliferation was evaluated by Glo cell viability assay and Ethynyl deoxyuridine (EdU) incorporation assay. For Glo cell viability assay, 3000 indicated cervical cancer cells were seeded per well in 96-well plates. At the indicated time cell viability was detected with the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) in accordance with the manufacturer\'s protocol. The luminescence value at each time point was acquired and used to plot cell proliferation curves. EdU incorporation assay was carried out using the EdU kit (Roche, Mannheim, Germany) in accordance with the manufacturer\'s protocol. The results were acquired and quantified using Zeiss photomicroscope (Carl Zeiss, Oberkochen, Germany).

Cell apoptosis assay
--------------------

Cell apoptosis was evaluated by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay. After being treated with 25 ng/ml doxorubicin (Selleck, Houston, TX, USA) for 24 hours, apoptosis of indicated cervical cancer cells was detected using TUNEL Cell Apoptosis Detection Kit (Beyotime, Jiangsu, China) in accordance with the manufacturer\'s protocol. The results were acquired and quantified using Zeiss photomicroscope (Carl Zeiss).

Cell migration assay
--------------------

Cell migration was evaluated by transwell assay. Indicated cervical cancer cells suspended in serum-free medium with 1 mg/ml Mitomycin C to inhibit cell proliferation were seeded in the upper chamber of a transwell (24-well insert, 8 µm pore size, Millipore, Bedford, MA, USA). Medium containing 20% fetal bovine serum was added to the lower chamber. After 48 hours incubation, the cells that migrated into the lower surface of the transwell insert were fixed, stained, photographed, and quantified with at least ten random fields.

*In vivo* xenograft experiment
------------------------------

Indicated cervical cancer cells were subcutaneously injected into the flanks of female athymic BALB/c nude mice (Laboratory Animal Resources, Chinese Academy of Sciences, Shanghai, China). Subcutaneous tumor growth was measured every seven days using a caliper. Tumor volume was calculated according to the equation V = a\*b\*b/2 (a, long axes; b, short axes). The Ethics Review Committee of Fujian Medical University reviewed and approved the use of animals.

Statistical analysis
--------------------

Statistical analyses were performed using GraphPad Prism software (version 5.0). For comparisons, Student\'s *t*-test, Wilcoxon signed-rank test, Mann-Whitney U test, receiver operating characteristic (ROC) curve analysis, and Pearson correlation analysis were carried out as indicated. *P* \< 0.05 was considered as statistically significant.

Results
=======

GIHCG is up-regulated in cervical cancer tissues and cell lines
---------------------------------------------------------------

The expression of GIHCG in 58 pairs of cervical cancer tissues and adjacent normal tissues was measured by qRT-PCR. As shown in Figure [1](#F1){ref-type="fig"}A, the expression of GIHCG was significantly up-regulated in cervical cancer tissues compared with adjacent normal tissues (*P* \< 0.0001). In addition, the expression of GIHCG in human normal cervical epithelial cell line (HCerEpiC) and cervical cancer cell lines (HeLa, SiHa, C-33A, and CaSki) was also measured by qRT-PCR. In accordance, the expression of GIHCG was significantly up-regulated in cervical cancer cell lines compared with normal cervical epithelial cell line (Figure [1](#F1){ref-type="fig"}B). These results revealed the up-regulation of GIHCG in cervical cancer.

GIHCG is up-regulated in the serum of cervical cancer patients and may serve as a novel diagnostic biomarker for cervical cancer
--------------------------------------------------------------------------------------------------------------------------------

Next, the expression of GIHCG in the serum of 80 cervical cancer patients and 80 age-matched healthy controls was measured by qRT-PCR. As shown in Figure [2](#F2){ref-type="fig"}A, the expression of serum GIHCG was also significantly up-regulated in cervical cancer patients compared with healthy controls (*P* \< 0.0001). To investigate whether serum GIHCG could serve as a non-invasive diagnostic biomarker for cervical cancer, receiver operating characteristic (ROC) curve analyses were performed. ROC curve showed accurate discrimination between cervical cancer patients and healthy controls, with an area under the ROC curve (AUC) of 0.9408 (95% CI: 0.9073-0.9743), a sensitivity of 88.75%, and a specificity of 87.50% (Figure [2](#F2){ref-type="fig"}B). These results revealed the up-regulation of serum GIHCG in cervical cancer patients and suggested that serum GIHCG may serve as a novel non-invasive diagnostic biomarker for cervical cancer.

GIHCG promotes cervical cancer cell proliferation, inhibits cell apoptosis, and promotes cell migration
-------------------------------------------------------------------------------------------------------

To investigate the biological roles of GIHCG in cervical cancer, we stably overexpressed GIHCG in HeLa cells by transfecting GIHCG overexpression vectors. The successful overexpression of GIHCG in HeLa cells was confirmed by qRT-PCR (Figure [3](#F3){ref-type="fig"}A). Cell proliferation was assessed by Glo cell viability assays and EdU incorporation assays. Glo cell viability assays displayed that enhanced expression of GIHCG increased cell viability of HeLa cells (Figure [3](#F3){ref-type="fig"}B). In accordance, EdU incorporation assays further displayed that enhanced expression of GIHCG promoted cell proliferation of HeLa cells (Figure [3](#F3){ref-type="fig"}C). Next, cell apoptosis was assessed by TUNEL assays. The results displayed that enhanced expression of GIHCG inhibited cell apoptosis of HeLa cells (Figure [3](#F3){ref-type="fig"}D). Moreover, cell migration was assessed by transwell assays. The results displayed that enhanced expression of GIHCG promoted cell migration of HeLa cells (Figure [3](#F3){ref-type="fig"}E). These results revealed that GIHCG functions as an oncogene in cervical cancer via promoting cell proliferation and migration, and inhibiting cell apoptosis.

Silencing GIHCG inhibits cervical cancer cell proliferation, induces cell apoptosis, and represses cell migration
-----------------------------------------------------------------------------------------------------------------

To further confirm the oncogenic roles of GIHCG in cervical cancer, we silenced GIHCG expression in CaSki cells by transfecting two independent GIHCG specific siRNAs. The successful knockdown of GIHCG in CaSki cells was confirmed by qRT-PCR (Figure [4](#F4){ref-type="fig"}A). Glo cell viability assays displayed that silencing GIHCG by two independent siRNAs both reduced cell viability of CaSki cells (Figure [4](#F4){ref-type="fig"}B). In accordance, EdU incorporation assays further displayed that silencing GIHCG by two independent siRNAs both inhibited cell proliferation of CaSki cells (Figure [4](#F4){ref-type="fig"}C). TUNEL assays displayed that silencing GIHCG by two independent siRNAs both induced cell apoptosis of CaSki cells (Figure [4](#F4){ref-type="fig"}D). Transwell migration assays displayed that silencing GIHCG by two independent siRNAs both inhibited cell migration of CaSki cells (Figure [4](#F4){ref-type="fig"}E). These results revealed that silencing GIHCG has tumor suppressive roles in cervical cancer via inhibiting cell proliferation and migration and inducing cell apoptosis.

GIHCG represses the expression of miR-200b in cervical cancer cells
-------------------------------------------------------------------

GIHCG is reported to repress the expression of miR-200b in hepatocellular carcinoma cells [@B33]. miR-200b is a well-known tumor suppressor in many cancers, including cervical cancer [@B35]. Therefore, we further investigated whether GIHCG also repressed miR-200b in cervical cancer cells and whether miR-200b is the mediator of the oncogenic roles of GIHCG in cervical cancer. The expression of miR-200b in GIHCG stably overexpressed and controlled HeLa cells was measured by qRT-PCR. As shown in Figure [5](#F5){ref-type="fig"}A, the expression of miR-200b was significantly reduced in GIHCG overexpressed cells compared with that in control cells. Reciprocally, silencing GIHCG using two dependent siRNAs both up-regulated the expression of miR-200b in CaSki cells (Figure [5](#F5){ref-type="fig"}B). To investigate whether the regulation of miR-200b by GIHCG also exists *in vivo*, the expression of miR-200b in the same 58 pairs of cervical cancer tissues and adjacent normal tissues used in Figure [1](#F1){ref-type="fig"}A was measured by qRT-PCR. The results displayed that the expression of miR-200b was significantly down-regulated in cervical cancer tissues compared with adjacent normal tissues (*P* \< 0.0001, Figure [5](#F5){ref-type="fig"}C). The correlation between miR-200b and GIHCG expression levels in these 58 cervical cancer tissues was examined by Pearson correlation analysis. The results displayed a statistically significant inverse correlation between miR-200b and GIHCG expression levels (r = -0.7933, *P* \< 0.0001, Figure [5](#F5){ref-type="fig"}D). Thus, these results revealed the repression of miR-200b by GIHCG in cervical cancer.

miR-200b reverses the oncogenic roles of GIHCG in cervical cancer *in vivo*
---------------------------------------------------------------------------

To investigate whether miR-200b is the mediator of the oncogenic roles of GIHCG in cervical cancer, we stably overexpressed miR-200b in GIHCG stably overexpressed HeLa cells via infecting miR-200b overexpression lentivirus. The successful overexpression of miR-200b in GIHCG stably overexpressed HeLa cells was confirmed by qRT-PCR (Figure [6](#F6){ref-type="fig"}A). These stably overexpressed and control HeLa cells were subcutaneously injected into immune-compromised nude mice. Tumor growth was monitored every seven days, and the results displayed that enhanced expression of GIHCG significantly promoted subcutaneous tumor growth, which was attenuated by miR-200b overexpression (Figure [6](#F6){ref-type="fig"}B). At 4-weeks after injection, the mice were sacrificed and the subcutaneous tumors were resected and weighed. The results displayed that enhanced expression of GIHCG significantly increased tumor weights, which was also attenuated by miR-200b overexpression (Figure [6](#F6){ref-type="fig"}C). Immunohistochemical staining of proliferation marker Ki67 in the subcutaneous tumors displayed that enhanced expression of GIHCG increased the number of Ki67-positive cells, which was attenuated by miR-200b overexpression (Figure [6](#F6){ref-type="fig"}D). TUNEL staining of the subcutaneous tumors displayed that enhanced expression of GIHCG reduced the number of TUNEL-positive apoptotic cells, which was also attenuated by miR-200b overexpression (Figure [6](#F6){ref-type="fig"}E). Thus, these results revealed the oncogenic roles of GIHCG in cervical cancer *in vivo* via promoting tumor growth, which could be reversed by miR-200b.

Discussion
==========

The alterations of protein-coding genes and signaling pathways in the initiation and progression of cervical cancer have been well recognized [@B36], [@B37]. The implications of lncRNAs in cervical cancer are relative much less recognized. Although several lncRNAs have been reported to be associated with cervical cancer, such as NCK1-AS1, GAS5, UFC1, SNHG16, and CCHE1, the expression, roles, and clinical significances of lncRNAs in cervical cancer remain largely unclear [@B38]-[@B42].

Recently, lncRNA GIHCG is reported to have oncogenic roles in liver cancer, tongue squamous cell carcinoma, and renal cell carcinoma (RCC) [@B33], [@B34], [@B43]. Sui et al reported that GIHCG is upregulated in liver cancer tissues and cell lines compared with adjacent normal liver tissues and normal liver cell lines. GIHCG promotes liver cancer proliferation and migration via inhibiting miR-200b/a/429 [@B33]. Ma et al reported that GIHCG is upregulated in tongue squamous cell carcinoma tissues and cell lines. GIHCG promotes tongue squamous cell carcinoma cell cycle, proliferation, and migration via inhibiting miR-429 [@B43]. Our previous study reported the up-regulation of GIHCG in RCC tissues compared with adjacent normal renal tissues. Furthermore, we identified the existence of GIHCG in the serum, and found that GIHCG is increased in the serum of RCC patients and could serve as a non-invasive diagnostic biomarker for RCC [@B34]. However, the clinical significances of GIHCG in cervical cancer are still unknown.

In this study, we first investigated the expression pattern of GIHCG in cervical cancer. We discovered that the expression of GIHCG is notably up-regulated in cervical cancer tissues compared with corresponding normal tissues, and also significantly up-regulated in cervical cancer cell lines compared with normal cervical epithelial cell line. Furthermore, we collected 80 cervical cancer patients\' serums before surgery and 80 serums from age-matched healthy controls. We discovered that serum GIHCG is remarkably up-regulated in cervical cancer patients compared with healthy controls. ROC curve analyses displayed that serum GIHCG could efficiently discriminate cervical cancer patients from healthy controls and suggested that serum GIHCG could serve as a non-invasive diagnostic biomarker for cervical cancer. Thus, this study provided a novel biomarker for the diagnosis of cervical cancer. Combining our previous study about the diagnostic significance of GIHCG for RCC, we proposed that the diagnostic values of GIHCG for cancers may be cancer-popular, but not cancer type-specific. More serum from various cancers patients are needed to elucidate this proposal.

The functions of GIHCG in cervical cancer are explored by *in vitro* and *in vivo* gain-of-function and loss-of-function assays. Our data revealed that overexpression of GIHCG promotes cervical cancer cell proliferation and migration and inhibits cervical cancer cell apoptosis. Depletion of GIHCG inhibits cervical cancer cell proliferation and migration and promotes cervical cancer cell apoptosis. Overexpression of GIHCG also promotes cervical cancer tumor growth *in vivo*. These data supported the oncogenic roles of GIHCG in cervical cancer and implied that targeting GIHCG may be a potential therapeutic strategy for cervical cancer.

Previous report showed that GIHCG epigenetically silenced miR-200b/a/429 expression in liver cancer [@B33]. miR-200b is a well-known tumor suppressor in many cancers via directly repressing several critical oncogenes [@B35]. In this study, we also found that GIHCG repressed the expression of miR-200b in cervical cancer. The expression of miR-200b is inversely correlated with the expression of GIHCG in cervical cancer tissues. Moreover, overexpression of miR-200b attenuated the oncogenic roles of GIHCG in promoting cervical cancer tumor growth *in vivo*. Thus, our data suggested that miR-200b at least partially mediated the roles of GIHCG in cervical cancer.

In conclusion, this study displayed that lncRNA GIHCG is up-regulated in cervical cancer tissues, cell lines, and serums. Serum GIHCG may serve as a novel non-invasive diagnostic biomarker for cervical cancer. Functionally, GIHCG promotes cervical cancer cell proliferation and migration, inhibits cervical cancer cell apoptosis, and promotes cervical cancer tumor growth *in vivo* via repressing miR-200b. Therefore, GIHCG functions as an oncogene and may serve as a potential therapeutic target in cervical cancer.
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![**GIHCG is up-regulated in cervical cancer tissues and cell lines.** (A) The expression of GIHCG in 58 pairs of cervical cancer tissues and adjacent normal tissues was measured by qRT-PCR. *P* \< 0.0001 by Wilcoxon signed-rank test. (B) the expression of GIHCG in human normal cervical epithelial cell line (HCerEpiC) and cervical cancer cell lines (HeLa, SiHa, C-33A, and CaSki) was measured by qRT-PCR. Results are displayed as mean ± SD based on three independent biological replicates. \*\**P* \< 0.01, \*\*\**P* \< 0.001 by Student\'s *t*-test.](jcav10p0672g001){#F1}

![**GIHCG is up-regulated in the serum of cervical cancer patients and may serve as a novel diagnostic biomarker for cervical cancer.** (A) The expression of GIHCG in the serum of 80 cervical cancer patients and 80 age-matched healthy controls was measured by qRT-PCR. *P* \< 0.0001 by Mann-Whitney U test. (B) ROC curve analysis of serum GIHCG for discrimination between cervical cancer patients and healthy controls (AUC: 0.9408, sensitivity: 88.75%, specificity: 87.50%). *P* \< 0.0001.](jcav10p0672g002){#F2}

![**GIHCG promotes cervical cancer cell proliferation, inhibits cell apoptosis, and promotes cell migration.** (A) The expression of GIHCG in GIHCG stably overexpressed and control HeLa cells was measured by qRT-PCR. (B) Cell viability of GIHCG stably overexpressed and control HeLa cells at indicated time was measured by Glo cell viability assays. (C) Cell proliferation of GIHCG stably overexpressed and control HeLa cells was measured by EdU incorporation assays. Red color indicates EdU-positive proliferative cells. Scale bars, 100 μm. (D) Cell apoptosis of GIHCG stably overexpressed and control HeLa cells was measured by TUNEL assays. Green color indicates TUNEL-positive apoptotic cells. Scale bars, 100 μm. (E) Cell migration of GIHCG stably overexpressed and control HeLa cells was measured by transwell migration assays. Scale bars, 100 μm. Results are displayed as mean ± SD based on three independent biological replicates. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 by Student\'s *t*-test.](jcav10p0672g003){#F3}

![**Silencing GIHCG inhibits cervical cancer cell proliferation, induces cell apoptosis, and represses cell migration.** (A) The expression of GIHCG in CaSki cells 48h after GIHCG siRNAs transfection was measured by qRT-PCR. (B) Cell viability of CaSki cells at indicated time after GIHCG siRNAs transfection was measured by Glo cell viability assays. (C) Cell proliferation of CaSki cells 48h after GIHCG siRNAs transfection was measured by EdU incorporation assays. Red color indicates EdU-positive proliferative cells. Scale bars, 100 μm. (D) Cell apoptosis of CaSki cells 48h after GIHCG siRNAs transfection was measured by TUNEL assays. Green color indicates TUNEL-positive apoptotic cells. Scale bars, 100 μm. (E) Cell migration of CaSki cells 48h after GIHCG siRNAs transfection was measured by transwell migration assays. Scale bars, 100 μm. Results are displayed as mean ± SD based on three independent biological replicates. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 by Student\'s *t*-test.](jcav10p0672g004){#F4}

![**GIHCG represses the expression of miR-200b in cervical cancer.** (A) The expression of miR-200b in GIHCG stably overexpressed and control HeLa cells was measured by qRT-PCR. (B) The expression of miR-200b in CaSki cells 48h after GIHCG siRNAs transfection was measured by qRT-PCR. For A-B, results are displayed as mean ± SD based on three independent biological replicates. \*\*\**P* \< 0.001 by Student\'s *t*-test. (C) The expression of miR-200b in 58 pairs of cervical cancer tissues and adjacent normal tissues was measured by qRT-PCR. *P* \< 0.0001 by Wilcoxon signed-rank test. (D) The correlation between miR-200b and GIHCG expression level in 58 cervical cancer tissues was analyzed. r = -0.7933, *P* \< 0.0001 by Pearson correlation analysis.](jcav10p0672g005){#F5}

![**Overexpression of miR-200b attenuates the oncogenic roles of GIHCG in cervical cancer *in vivo*.** (A) The expression of miR-200b in GIHCG and miR-200b concurrently overexpressed and control HeLa cells was measured by qRT-PCR. Results are displayed as mean ± SD based on three independent biological replicates. \*\*\**P* \< 0.001 by Student\'s *t*-test. (B) GIHCG and miR-200b stably overexpressed and control HeLa cells were subcutaneously injected into nude mice. Tumor volumes were monitored every seven days. (C) The subcutaneous tumor weights were measured at 4-weeks after injection. (D) Immunohistochemical staining of Ki67 in subcutaneous tumors formed by GIHCG and miR-200b stably overexpressed and control HeLa cells. Scale bars, 50 μm. (E) TUNEL staining of subcutaneous tumors formed by GIHCG and miR-200b stably overexpressed and control HeLa cells. Scale bars, 50 μm. For B-E, results are displayed as mean ± SD based on n = 5 mice in each group. \**P* \< 0.05, \*\**P* \< 0.01 by Mann-Whitney U test.](jcav10p0672g006){#F6}
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